WEED vs. OGI, GUD, ACB, CRON, TLRY, BHC, WELL, SIA, DNTL, and EXE
Should you be buying Canopy Growth stock or one of its competitors? The main competitors of Canopy Growth include Organigram (OGI), Knight Therapeutics (GUD), Aurora Cannabis (ACB), Cronos Group (CRON), Tilray Brands (TLRY), Bausch Health Companies (BHC), WELL Health Technologies (WELL), Sienna Senior Living (SIA), dentalcorp (DNTL), and Extendicare (EXE). These companies are all part of the "medical" sector.
Canopy Growth (TSE:WEED) and Organigram (TSE:OGI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, community ranking, media sentiment, dividends, risk, profitability and institutional ownership.
Canopy Growth has a net margin of 0.00% compared to Organigram's net margin of -153.80%. Organigram's return on equity of -54.53% beat Canopy Growth's return on equity.
Organigram has lower revenue, but higher earnings than Canopy Growth. Organigram is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.
Canopy Growth has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500. Comparatively, Organigram has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.
Canopy Growth received 593 more outperform votes than Organigram when rated by MarketBeat users. Likewise, 62.44% of users gave Canopy Growth an outperform vote while only 44.34% of users gave Organigram an outperform vote.
Canopy Growth currently has a consensus price target of C$3.20, indicating a potential downside of 78.39%. Organigram has a consensus price target of C$3.76, indicating a potential upside of 38.68%. Given Organigram's stronger consensus rating and higher possible upside, analysts plainly believe Organigram is more favorable than Canopy Growth.
In the previous week, Organigram had 15 more articles in the media than Canopy Growth. MarketBeat recorded 20 mentions for Organigram and 5 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 0.82 beat Organigram's score of 0.12 indicating that Canopy Growth is being referred to more favorably in the media.
4.3% of Canopy Growth shares are held by institutional investors. Comparatively, 9.0% of Organigram shares are held by institutional investors. 0.2% of Canopy Growth shares are held by insiders. Comparatively, 27.3% of Organigram shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Organigram beats Canopy Growth on 10 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding WEED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Canopy Growth Competitors List
Related Companies and Tools
